Abstract: Secukinumab was the first fully human anti-interleukin-17a monoclonal antibody and successfully treated moderate-severe psoriasis. These new targeted medications are becoming more popular, but long-term side effects are not entirely clear. Dyshidrotic eczema and pompholyx are rare variants of dermatitis characterized by vesicles or bullae on the palms, soles and sides of the fingers. At present, the cases of patients with similar skin rashes after using secukinumab in the world have been reported. Herein, we present one case of erythroderma, accompany with dyshidrotic eczema in a patient with secukinumab for psoriasis.

Key words: secukinumab, plaque psoriasis, dyshidrotic eczema